Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.24B

Market cap19.24B

Price-Earnings ratio

15.12

Price-Earnings ratio15.12

Dividend yield

—

Dividend yield—

Average volume

1.28M

Average volume1.28M

High today

$98.20

High today$98.20

Low today

$96.00

Low today$96.00

Open price

$96.80

Open price$96.80

Volume

1.01M

Volume1.01M

52 Week high

$112.29

52 Week high$112.29

52 Week low

$57.29

52 Week low$57.29

Stock Snapshot

With a market cap of 19.24B, Incyte(INCY) trades at $96.74. The stock has a price-to-earnings ratio of 15.12.

On 2026-04-23, Incyte(INCY) stock moved within a range of $96.00 to $98.20. With shares now at $96.74, the stock is trading +0.8% above its intraday low and -1.5% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.01M, versus its average volume of 1.28M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $57.29.

INCY News

The Motley Fool 11h

Incyte Q4 2024 Earnings Transcript

Image source: The Motley Fool. Monday, February 10, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Herve Hoppenot President, Head of Research &...

TipRanks 1d

Top Incyte Executive Makes Bold Move With Major Stock Sale

New insider activity at Incyte ( (INCY) ) has taken place on April 21, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharper dec...

Simply Wall St 2d

Should Positive DLBCL Data And New IO Collaboration Require Action From Incyte Investors?

Incyte has reported positive Phase 3 results for tafasitamab (Monjuvi/Minjuvi) in first-line diffuse large B-cell lymphoma, with full data to be presented at th...

Analyst ratings

52%

of 29 ratings

Buy

37.9%

Hold

51.7%

Sell

10.3%

More INCY News

TipRanks 2d

Incyte to announce full results from Phase 3 tafasitamab study at ASCO

Incyte (INCY) announced that full results from the Phase 3 pivotal study evaluating tafasitamab in first-line diffuse large b-cell lymphoma will be featured as...

Simply Wall St 6d

Is It Too Late To Consider Incyte After Its 63.8% One Year Rally?

If you are wondering whether Incyte’s current share price lines up with its underlying worth, the key question is how the market is valuing its future cash flow...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.